Anti Inflammatory News and Research

RSS

BioElectronics and SAY-GIN sign agreement to sell ActiPatch and Allay products in Turkey

BioElectronics Corp., the maker of inexpensive, disposable, drug-free anti-inflammatory devices, today announced it has reached an agreement with SAY-GIN Ozel Egtim Yayincilik Ticaret Hizmetleri (SAY-GIN) for distribution of its ActiPatch and Allay products in Turkey.

9 Feb 2010

Reliv International adds new products to its portfolio

Reliv International, Inc. introduced three new products to its Relivables line at the company's national conference here today. The products represent the first extension of the Relivables line since it was introduced last August.

6 Feb 2010

Sistemic to develop SistemRNA compound-centric drug discovery technology with closed series A funds

Fast growing Scottish biotech company Sistemic Ltd today announced that it had closed a series A funding round with lead investors ChimeraBio and the Scottish Enterprise Scottish Co-Investment Fund. The company will use the funding to further develop its proprietary SistemRNA compound-centric drug discovery technology. Using SistemRNA shortens the odds in drug discovery by enabling far more accurate prediction of potential drug indications, interactions and side effects.

4 Feb 2010

Anti-inflammatory plant derivative could play a role in cancer treatment, say MCG researchers

Medical College of Georgia researchers are seeking to refine cancer treatment with an anti-inflammatory plant derivative long used in Chinese medicine.

4 Feb 2010

Javelin Pharmaceuticals' NDA for Dyloject Injection accepted for formal review

Javelin Pharmaceuticals, Inc., a leading developer and marketer of specialty pharmaceutical products for pain management, today announced that its New Drug Application (NDA) submitted on December 2, 2009 to the US Food and Drug Administration (FDA) for its investigational product candidate, Dyloject™ (diclofenac sodium) Injection, has been accepted for formal review.

2 Feb 2010

Safer bone marrow transplants

If a team of American scientists are right, bone marrow transplants may become safer and more available to people in need of donations. In a new research paper appearing in the February 2010 print edition of the Journal of Leukocyte Biology (http://www.jleukbio.org), they explain how an anti-inflammatory agent called "ATL146e" may significantly improve the likelihood of success for bone marrow transplants by preventing or halting the progression of graft-versus-host disease, a complication of bone marrow transplants in which the donor marrow attacks the host. Although very rare, graft-versus-host disease can also occur after blood transfusions.

2 Feb 2010

Conatus Pharmaceuticals initiates combination trial of CTS-1027 with pegylated interferon and ribavirin for HCV

Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys®) and ribavirin (Copegus®) in refractory HCV patients. Antiviral activity, safety and tolerability of the triple combination will be assessed after up to 48 weeks of therapy.

28 Jan 2010

Celgene reports total revenue of $758M for fourth-quarter of 2009

Celgene Corporation announced non-GAAP (Generally Accepted Accounting Principles) net income of $290.3 million, or non-GAAP diluted earnings per share of $0.62 for the quarter ended December 31, 2009. Non-GAAP net income for the fourth quarter of 2008 was $200.9 million or non-GAAP diluted earnings per share of $0.43. Based on U.S. GAAP, Celgene reported net income of $254.2 million, or diluted earnings per share of $0.54 for the quarter ended December 31, 2009. GAAP net loss for the fourth quarter of 2008 was $149.3 million, or diluted loss per share of $0.33.

28 Jan 2010

Anacor Pharmaceuticals to present data on its PDE4 inhibitor at the Cytokines and Inflammation Conference

Anacor Pharmaceuticals announced today that it will present a poster and oral presentation on a novel systemic anti-inflammatory candidate, AN6415, at the upcoming 8th Cytokines and Inflammation Conference, taking place January 28-29, 2010 in La Jolla, California.

28 Jan 2010

Research suggests pomegranate seed extract could stimulate uterine contractions

The team identified beta-sitosterol - a steroid that can inhibit the absorption of cholesterol in the intestine - as the main constituent of pomegranate seed extract. The research suggests that pomegranate extract could be used as a natural stimulant to encourage the uterus to contract during labour.

28 Jan 2010

GENFIT's GFT505 exhibits potential to address unmet needs in prediabetic and diabetic patients

GENFIT, a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and neurodegenerative diseases, today announces positive results from a recently completed clinical trial demonstrating the activity of GFT505 on glucose homeostasis. Results from the clinical trial (GFT505-2094) clearly demonstrate the potential of the drug candidate to reduce global cardiovascular risk in prediabetic patients who suffer from impaired fasting plasma glucose, impaired glucose tolerance, and abdominal obesity.

28 Jan 2010

Regular exercise and drinking tea may reduce depression in breast cancer patients

Breast cancer patients who exercise and drink tea on a regular basis may be less likely to suffer from depression than other patients, according to a new study led by Xiao Ou Shu, M.D., Ph.D., professor of Medicine, Vanderbilt-Ingram Cancer Center. Xiaoli Chen, M.D., a post-doctoral fellow, was first author of the study published in the January issue of the Journal of Clinical Oncology.

28 Jan 2010

USPTO grants Cenestra Health patent relating to high-purity omega-3 fatty acid formulations

Cenestra Health announced today that the U.S. Patent and Trademark Office has issued a key patent related to the company's high-purity omega-3 fatty acid formulations and their methods of use. U.S. Patent No. 7652068, entitled "Omega-3 Fatty Acid Formulations," covers a unique, high-purity formulation of the omega-3 fatty acids EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid).

27 Jan 2010

BioElectronics signs contract with YesDTC Holdings to enter the Japanese market

BioElectronics Corp., the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced the signing of a contract with YesDTC Holdings, Inc. (YESD.OB) to enter the Japanese market and receipt of the single largest product order and revenue commitment in company history.

26 Jan 2010

NicOx receives EMEA approval for naproxcinod MAA

NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.

22 Jan 2010

Mice study shows obesity can increase risk of developing liver cancer

Obesity comes with plenty of health risks, but there's one that's perhaps not so well known: an increased risk of developing cancer, and especially certain types of cancer like liver cancer. Now, a group of researchers reporting in the January 22nd issue of the journal Cell, a Cell Press publication, have confirmed in mice that obesity does indeed act as a "bona fide tumor promoter." They also have good evidence to explain how that happens.

22 Jan 2010

Endo Pharmaceuticals' partners receive Paragraph IV Certification Notice regarding LIDODERM

Endo Pharmaceuticals announced today that its partners, Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA, Inc. have received a Paragraph IV Certification Notice from Watson Laboratories, Inc. advising of the filing of an Abbreviated New Drug Application (ANDA) for a generic version of LIDODERM® (lidocaine topical patch 5%).

20 Jan 2010

Repeated exposure to tobacco smoke makes lung cancer much worse

Repeated exposure to tobacco smoke makes lung cancer much worse, and one reason is that it steps up inflammation in the lung. Scientists at the University of California, San Diego School of Medicine have found that mice with early lung cancer lesions that were repeatedly exposed to tobacco smoke developed larger tumors - and developed tumors more quickly - than unexposed animals.

19 Jan 2010

The Methodist Hospital initiates program on nanotechnology in orthopedics and spine surgery

A new research program at The Methodist Hospital in Houston is the nation's first dedicated solely to advancing nanotechnology in orthopedics and spine surgery.

19 Jan 2010

Alcon to acquire U.S. rights to Sirion Therapeutics' Durezol and Zirgan

Alcon, the world’s leader in eye care, announced today that it will purchase the rights in the United States for two FDA-approved topical eye care products from Sirion Therapeutics, Inc. The two products purchased are Durezol™, a marketed ophthalmic corticosteroid approved for the treatment of inflammation and pain associated with eye surgery, and Zirgan™, a recently approved antiviral for the treatment of acute herpetic keratitis (corneal ulcers).

18 Jan 2010

Anti Inflammatory News and Research

BioElectronics and SAY-GIN sign agreement to sell ActiPatch and Allay products in Turkey

Reliv International adds new products to its portfolio

Sistemic to develop SistemRNA compound-centric drug discovery technology with closed series A funds

Anti-inflammatory plant derivative could play a role in cancer treatment, say MCG researchers

Javelin Pharmaceuticals' NDA for Dyloject Injection accepted for formal review

Safer bone marrow transplants

Conatus Pharmaceuticals initiates combination trial of CTS-1027 with pegylated interferon and ribavirin for HCV

Celgene reports total revenue of $758M for fourth-quarter of 2009

Anacor Pharmaceuticals to present data on its PDE4 inhibitor at the Cytokines and Inflammation Conference

Research suggests pomegranate seed extract could stimulate uterine contractions

GENFIT's GFT505 exhibits potential to address unmet needs in prediabetic and diabetic patients

Regular exercise and drinking tea may reduce depression in breast cancer patients

USPTO grants Cenestra Health patent relating to high-purity omega-3 fatty acid formulations

BioElectronics signs contract with YesDTC Holdings to enter the Japanese market

NicOx receives EMEA approval for naproxcinod MAA

Mice study shows obesity can increase risk of developing liver cancer

Endo Pharmaceuticals' partners receive Paragraph IV Certification Notice regarding LIDODERM

Repeated exposure to tobacco smoke makes lung cancer much worse

The Methodist Hospital initiates program on nanotechnology in orthopedics and spine surgery

Alcon to acquire U.S. rights to Sirion Therapeutics' Durezol and Zirgan

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News